Effects of nivolumab alone or combination with molecular targeting agents for recurrent and refractory endometrial cancers with biomarker analyses.

e17124Background: The immunotherapydrug, nivolumab, is now approved for several metastatic cancers, and has resulted in responses previously not seen with these cancers. Molecular targeting agents...